A Simple Pill, A Striking Difference

Nearly one in four stroke survivors will have another stroke, and uncontrolled high blood pressure is the single most powerful modifiable risk factor driving that recurrence. Now, a new clinical trial suggests that a decades-old, inexpensive medication could meaningfully change those odds โ€” at least when it comes to getting blood pressure under control.

The REDUCE trial examined whether adding spironolactone, a medication commonly known as a water pill, could lower blood pressure in stroke survivors whose readings remained high despite treatment. The results, presented as a late-breaking abstract at the American Heart Association’s Scientific Sessions 2026 on November 7, 2026, were striking: the secondary prevention blood pressure target of less than 130/80 mmHg was achieved by 52% of patients receiving spironolactone, compared with 30% of those receiving usual care.

What the Trial Found

REDUCE randomized 160 patients following ischemic stroke or intracerebral hemorrhage across five U.S. centers to either a spironolactone-based blood pressure regimen or standard care, in which treating clinicians received a letter summarizing 2017 ACC/AHA high blood pressure guideline recommendations for stroke survivors. Patients assigned to spironolactone received 25 mg daily, with the option to increase the dose to 50 mg.

Results showed a mean difference in home systolic blood pressure of 7.7 mmHg at three months and 6.9 mmHg at six months compared to standard care, demonstrating that the effect wasn’t just a short-term blip โ€” it held up over half a year. Diastolic blood pressure also improved at three months with spironolactone compared with standard post-stroke care. In an exploratory analysis, the blood pressure drop was larger in people who started the medication within three months after a stroke, prompting researchers to say they hope these findings encourage health care professionals to consider adding spironolactone sooner.

The trial enrolled 160 adult stroke survivors with an average age of 63, of whom 38% were women and roughly 30% self-identified as Black adults and 16% as Hispanic adults โ€” groups that are disproportionately affected by both stroke and hypertension, making the trial’s diversity particularly relevant.

The Cost Factor

Spironolactone is a cheap diuretic priced under $20 monthly, which sets it apart from many newer cardiovascular medications that can cost hundreds of dollars per month. That accessibility matters enormously for a patient population that is already managing the financial and physical burdens of stroke recovery. Lowering blood pressure is the most important step in preventing another stroke, yet many survivors struggle to reach recommended blood pressure targets after a stroke. A widely available, affordable option that meaningfully improves the odds of hitting those targets could have real-world impact at scale.

Important Caveats Remain

The trial ended early with 160 participants instead of the planned 200, and about 15% did not have blood pressure readings available at the three-month mark. Participants taking spironolactone were also taking slightly more blood pressure medications overall than those receiving usual care, a wrinkle that makes it harder to isolate spironolactone’s contribution entirely.

The study was not designed to determine whether spironolactone prevents another stroke or heart attack; researchers said larger and longer studies are needed to answer that question. That distinction is critical. Better blood pressure numbers are a well-established proxy for better outcomes, but a definitive link to actual stroke prevention will require a larger, longer trial. For the 7 million Americans living with the aftermath of a previous stroke, that trial cannot come soon enough. In the meantime, today’s findings give clinicians a compelling, evidence-backed reason to revisit whether stroke patients with stubborn hypertension are getting every tool available.